Tirzepatide vs. Semaglutide for Obesity and Glycemic Control: A Structured Review

Bottom line: Tirzepatide's dual GIP/GLP-1 receptor agonism consistently outperforms semaglutide on weight loss and HbA1c reduction, making it the preferred first-line incretin therapy when maximal metabolic benefit is the clinical goal.

Tirzepatide (Mounjaro/Zepbound) is a once-weekly injectable peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, while semaglutide (Ozempic/Wegovy) selectively targets the GLP-1 receptor alone. Both are approved for type 2 diabetes and obesity, but an emerging body of evidence suggests the dual-incretin approach may offer a meaningful efficacy advantage.

Key Findings

A structured review published in Frontiers in Medicine (2026) synthesized data from the SURPASS and SURMOUNT programs for tirzepatide alongside the STEP and SUSTAIN programs for semaglutide, as well as real-world comparative studies and the head-to-head SURMOUNT-5 trial.¹

Weight loss: Tirzepatide 15 mg produced mean body weight reductions of 20.9–22.5% across SURMOUNT trials versus 15.0–16.9% with semaglutide 2.4 mg in the STEP program. In the direct comparison SURMOUNT-5 trial, tirzepatide 15 mg achieved a −20.2% weight reduction versus −13.7% for semaglutide 2.4 mg (estimated treatment difference −6.5 percentage points, 95% CI −7.8 to −5.2, p < 0.001).¹

Glycemic control: In patients with type 2 diabetes, tirzepatide 15 mg lowered HbA1c by approximately 2.1–2.4 percentage points compared with 1.5–1.8 percentage points for semaglutide 1.0–2.0 mg. The proportion of patients achieving HbA1c < 5.7% (normal range) was roughly double with tirzepatide at the highest dose.¹

Cardiovascular outcomes: The SURPASS-CVOT data showed tirzepatide reduced the composite risk of major adverse cardiovascular events (MACE) by 13% relative to dulaglutide (HR 0.87, 95% CI 0.79–0.96). Semaglutide demonstrated a 20% MACE reduction versus placebo in SELECT (HR 0.80, 95% CI 0.72–0.90). Direct cardiovascular comparison between the two agents remains unavailable.¹

Safety: Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common with both agents. Discontinuation rates due to adverse events were 4–7% across both drug programs. No new safety signals were identified for either agent.¹

Why This Matters

The incretin-based obesity and diabetes landscape is evolving rapidly. For clinicians choosing between these two peptide therapies, the evidence increasingly supports tirzepatide when maximal weight reduction and glycemic lowering are prioritized. However, semaglutide's longer post-marketing track record, broader insurance coverage, and oral formulation (Rybelsus) provide practical advantages for many patients.

Clinical implication: When the primary treatment goal is aggressive weight loss or glycemic normalization, tirzepatide should be considered first. Semaglutide remains an excellent option when access, cost, or oral administration is the deciding factor.

References

1. Tirzepatide vs. Semaglutide for Obesity, Glycemic control, and Cardiovascular Outcomes: A Structured Review. Frontiers in Medicine. 2026. DOI: 10.3389/fmed.2026.1764664